Browse the evidence

Combination therapy using GLP-1 receptor agonists with other hormones (GIP, GCG, or PYY) mimics the beneficial hormonal effects of gastric bypass surgery in non-surgical patients.

New combination drugs that activate multiple gut hormone receptors (like GLP-1, GIP, and Glucagon) are showing strong results in clinical trials for weight loss and blood sugar control, offering a non-surgical alternative to gastric bypass.

Fasting induces a metabolic switch from glycogenolysis to gluconeogenesis, lipolysis, and ketogenesis, which is considered a main driver of the metabolic health benefits provided by IF.

During fasting, your body switches from burning sugar to burning fat and producing ketones. This metabolic shift is likely why fasting can be healthy, even if it doesn't always lead to more weight loss than just eating less.

Daily ingestion of yogurt containing heat-treated Lactobacillus plantarum OLL2712 (≥5×10^9 cells) for 12 weeks significantly reduces HbA1c levels in prediabetic adults compared to placebo, primarily by preventing the aggravation of chronic inflammation and insulin resistance.

If you are prediabetic, eating 112 grams of yogurt containing heat-treated Lactobacillus plantarum OLL2712 every day for 3 months can help lower your average blood sugar (HbA1c) more than eating regular yogurt. It works by calming chronic inflammation that drives insulin resistance. You do not need to change your diet or exercise routine for this to work, but you should maintain your normal habits.

In prediabetic adults with higher baseline fasting blood glucose (≥107 mg/dL) or insulin resistance (HOMA-IR > 1.6), daily ingestion of heat-treated Lactobacillus plantarum OLL2712 significantly reduces fasting blood glucose and glycoalbumin levels, whereas no significant change occurs in the general population with lower baseline glucose.

If you are prediabetic and have higher fasting blood sugar or insulin resistance, adding this specific yogurt to your daily routine for 3 months may help lower your fasting blood sugar. If your baseline blood sugar is already in the normal range, you might not see a change in fasting levels, though your average blood sugar (HbA1c) may still improve slightly.

Obesity and Type 2 Diabetes are associated with altered secretion patterns of enteroendocrine hormones, specifically decreased GLP-1 and PYY, and increased ghrelin.

In obesity and diabetes, your gut's natural hormone signals are often disrupted, with less 'satiety' hormone (GLP-1) and more 'hunger' hormone (ghrelin). This contributes to the difficulty in managing weight.

Fructose consumption, particularly in large amounts or from added sugars, stimulates hepatic de novo lipogenesis and VLDL-triglyceride secretion, increasing intrahepatic fat and cardiovascular risk, whereas glucose and starch have different, often less adverse, metabolic profiles.

Limit added sugars, particularly those high in fructose (like HFCS and sucrose), as they can promote liver fat accumulation and high triglycerides. While whole fruits are healthy due to fiber, be mindful of concentrated fructose sources. Physical activity can mitigate some of these effects by increasing fructose oxidation.

GLP-1 RAs reduce blood pressure and albuminuria in patients with CKD and overweight/obesity, contributing to kidney and cardiovascular protection.

GLP-1 RAs can help lower your blood pressure and reduce protein in your urine (albuminuria), which are important markers for kidney and heart health. This benefit is partly due to weight loss but also direct effects of the medication.

Gut hormones (GLP-1, GIP, CCK, PYY, OXM) regulate food intake and energy homeostasis by acting on the hypothalamus and brainstem via direct circulation or vagus nerve signaling, while ghrelin stimulates appetite.

Understanding that gut hormones like GLP-1 and GIP signal satiety to the brain helps explain why medications mimicking these hormones (like semaglutide and tirzepatide) are effective for weight loss. Conversely, ghrelin signals hunger. This biological basis supports the use of drugs that target these pathways.

NNC9204-1177, a glucagon/GLP-1 receptor co-agonist, produces dose-dependent, clinically relevant weight loss (up to 12.6%) in adults with overweight or obesity, but its clinical development was halted due to unexpected safety signals including increased heart rate, impaired glucose tolerance, and elevated inflammatory markers.

NNC9204-1177 is not available for clinical use because it caused unacceptable side effects like rapid heart rate and inflammation, despite causing significant weight loss. Do not seek this specific compound. However, the mechanism (glucagon/GLP-1 co-agonism) suggests that combining these pathways can be more effective for weight loss than GLP-1 alone, provided safety is managed. Current approved GLP-1 agonists (like semaglutide) do not have this glucagon component and thus avoid this specific safety profile.

GLP-1 receptor agonists (GLP-1RAs) significantly reduce liver fat content and improve histological markers of NASH (resolution without fibrosis worsening) in patients with NAFLD, with efficacy demonstrated across liraglutide, semaglutide, and tirzepatide.

If you have fatty liver disease (NAFLD) or NASH, GLP-1 medications like liraglutide, semaglutide, or tirzepatide are proven to reduce liver fat and improve liver health, often more effectively than placebo. These drugs work through hormonal mechanisms that reduce liver fat independently of weight loss in some cases. While gastrointestinal side effects like nausea are common, they are often manageable. Consult a doctor to see if you are a candidate, especially if you also have Type 2 Diabetes or obesity.

The combination of bupropion and naltrexone reduces body weight by stimulating POMC neurons to decrease energy intake and increase expenditure, with naltrexone blocking negative feedback to enhance this effect.

Bupropion/naltrexone is a combination pill that helps reduce appetite and increase energy expenditure by acting on brain pathways. It is effective for weight loss in people with obesity and comorbidities like hypertension or diabetes. However, it is not suitable for everyone, particularly those with a history of seizures or eating disorders. Consult your doctor to determine if it is safe for you.

The co-ingestion of protein and calcium produces a synergistic, potent stimulation of endogenous GLP-1 secretion that exceeds the effects of either nutrient alone.

To maximize your body's natural appetite-suppressing hormone (GLP-1), combine protein and calcium in your meals. Research shows this combination triggers a much stronger hormonal response than eating protein or calcium alone. This is a natural, side-effect-free way to support satiety and metabolic health.

Female sex is significantly associated with a hyper-response (>15% total body weight loss) to subcutaneous GLP-1 analogue therapy compared to non-response, whereas male sex is not.

If you are a woman taking a GLP-1 medication like semaglutide or liraglutide for obesity, you are statistically more likely to achieve significant weight loss (hyper-response) than a man taking the same medication. This is likely due to physiological differences in how your body processes the drug and regulates appetite hormones. Men may need higher doses to achieve similar results. If you are not losing weight, discuss dose adjustment or alternative treatments with your doctor rather than stopping abruptly.

Tirzepatide treatment in adults with obesity but without pre-existing type 2 diabetes significantly reduces the incidence of new-onset type 2 diabetes compared to semaglutide.

If you have obesity and are at risk for type 2 diabetes, tirzepatide may be a more effective option than semaglutide for preventing the onset of the disease. This is based on real-world data showing a 27% lower risk of developing type 2 diabetes with tirzepatide compared to semaglutide over a one-year follow-up period. Consult your doctor to see if this treatment is appropriate for you.

Tirzepatide treatment in adults with pre-existing type 2 diabetes significantly reduces the risk of major adverse cardiovascular events (MACE), including all-cause mortality and cerebral infarction, compared to semaglutide.

If you have type 2 diabetes, tirzepatide may offer greater cardiovascular protection than semaglutide, including a lower risk of heart attack, stroke, and death. This is based on real-world data showing a 46% lower risk of major adverse cardiovascular events with tirzepatide compared to semaglutide over a one-year follow-up period. Consult your doctor to see if this treatment is appropriate for you.

Modifying the sequence of macronutrient ingestion (specifically consuming protein before carbohydrates) improves post-prandial glycemic control by enhancing GLP-1 secretion and delaying gastric emptying, independent of total caloric intake.

To manage blood sugar spikes, start your meal with protein (meat/fish) or vegetables before eating carbohydrates (rice/pasta). This simple sequencing triggers beneficial hormones (GLP-1) that slow down digestion and stabilize glucose levels, even if the total food amount remains the same.

GLP-1 receptor agonists (GLP-1RAs) reduce the incidence of major adverse renal events (specifically new-onset macroalbuminuria and eGFR decline) in patients with type 2 diabetes, independent of glycemic control.

If you have Type 2 Diabetes and are at risk for kidney disease (especially if you already have high albumin in your urine or reduced kidney function), GLP-1 receptor agonists (like Semaglutide or Liraglutide) are a strong treatment option. They protect your kidneys through multiple mechanisms beyond just lowering blood sugar, including reducing inflammation and sodium retention. Clinical trials show they significantly lower the risk of serious kidney events. Discuss once-weekly options with your doctor to minimize injection burden.

The association between high carbohydrate intake and increased CVD risk is significantly stronger in Asian populations (1.52-fold increase) compared to non-Asian populations (no significant association), with risk escalating dramatically when carbohydrate intake exceeds 60% of total energy.

If you are of Asian descent, be particularly mindful of your carbohydrate intake. The risk of heart disease increases significantly if carbohydrates make up more than 60% of your calories. Consider reducing your intake of refined carbohydrates and rice to lower this risk.

Phentermine/topiramate combination therapy results in significant weight loss but is associated with increased heart rate and potential psychiatric side effects.

Phentermine/topiramate is a combination pill that can lead to significant weight loss. However, it can increase your heart rate and cause psychiatric side effects like anxiety or depression. It requires careful monitoring by a doctor, and if you don't lose enough weight after a few months, the treatment may be stopped.

Bariatric surgery, particularly Roux-en-Y gastric bypass and biliopancreatic diversion, induces Type 2 Diabetes remission in a majority of patients through mechanisms exceeding simple caloric restriction, including hormonal changes (GLP-1, PYY) and altered gut microbiome.

For eligible patients with obesity and T2DM, bariatric surgery is the most potent intervention for achieving remission, often outperforming medication. It works by altering gut hormones that improve insulin sensitivity, not just by making the stomach smaller. Consultation with a bariatric specialist is required to assess eligibility based on BMI and diabetes duration.

Dual-agonists (GLP-1R/GIPR) and tri-agonists (GLP-1R/GIPR/GCGR) provide superior weight loss and cardiometabolic risk factor improvement (blood pressure, lipids) compared to GLP-1RAs alone, though their direct impact on hard cardiovascular outcomes (MACE) is still under investigation.

Newer medications like Tirzepatide (a dual agonist) may offer greater weight loss and improvements in blood pressure and cholesterol than older GLP-1 drugs. However, long-term data on whether this translates to fewer heart attacks or strokes is still being collected. If standard GLP-1s are not achieving your metabolic goals, discuss these newer options with your doctor.

Low-calorie sweeteners do not negatively affect post-prandial glucose or insulin levels in healthy individuals or those with diabetes.

If you have diabetes or are concerned about blood sugar spikes, LCS are a safe alternative to sugar. They do not raise blood glucose or insulin levels, making them suitable for managing diabetes while still enjoying sweet tastes.

GLP-1 receptor agonists improve hepatic steatosis and MASH resolution primarily through weight loss and direct inhibition of hepatic de novo lipogenesis.

GLP-1 agonists like semaglutide and liraglutide are effective treatments for MASH, achieving resolution in a significant portion of patients. They work by reducing liver fat through both weight loss and direct metabolic effects. Expect potential gastrointestinal side effects, which are usually manageable.

In real-world clinical practice, semaglutide produces attenuated weight loss (average 4.44%) compared to clinical trials, with diabetes mellitus diagnosis significantly reducing efficacy while linaclotide use and prediabetes are associated with enhanced weight loss.

If you are taking semaglutide in a standard clinical setting, expect an average weight loss of around 4-5% over a year, which is less than the 10-15% often cited from clinical trials. This difference is largely due to the lack of intensive lifestyle counseling provided in routine care. If you have diabetes, your weight loss may be further reduced, whereas having prediabetes or taking linaclotide might actually help you lose more weight.